<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1894">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04359862</url>
  </required_header>
  <id_info>
    <org_study_id>SEVO-COVID19</org_study_id>
    <nct_id>NCT04359862</nct_id>
  </id_info>
  <brief_title>Sedation With Sevoflurane Versus Propofol in Patients With Acute Respiratory Distress Syndrome Caused by COVID19 Infection</brief_title>
  <acronym>SEVO-COVID19</acronym>
  <official_title>Sedation With Sevoflurane Versus Propofol in Patients With Acute Respiratory Distress Syndrome Caused by COVID19 Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundación para la Investigación del Hospital Clínico de Valencia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fundación para la Investigación del Hospital Clínico de Valencia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      It is a multicenter, national, randomized 1:1 ratio, controlled, parallel, open study.

      Patients with severe ARDS-CoVid19 will be included in the trial within the first 24 hours.

      Patients will be randomized to one of the treatment groups:

        -  SEV group: 25 patients with Sevoflurane sedation by inhalation, starting at 6 ml/h and
           changing every 15 minutes until an adequate level of sedation is achieved (BIS 40-50)

        -  PRO group: 25 patients standard sedation with intravenous propofol, starting with 2
           mg/kg/h and changing every 15 minutes until an adequate level of sedation is achieved (
           BIS 40-50)
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 16, 2020</start_date>
  <completion_date type="Anticipated">September 16, 2020</completion_date>
  <primary_completion_date type="Anticipated">August 16, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Multicenter, national, randomized, 1:1 ratio, controlled, parallel, open study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PaO2/FiO2</measure>
    <time_frame>Day 2</time_frame>
    <description>To evaluate the effect of 48-hour treatment with inhaled sevoflurane on arterial oxygenation, assessed by PaO2/FiO2 on day two, in patients with ARDS-CoVid19</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>TNFα</measure>
    <time_frame>Day 2</time_frame>
    <description>To quantify the effects of sevoflurane on pro-inflammatory cytokine levels during ARDS-CoVid19</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IL-1b</measure>
    <time_frame>Day 2</time_frame>
    <description>To quantify the effects of sevoflurane on pro-inflammatory cytokine levels during ARDS-CoVid19</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IL-6</measure>
    <time_frame>Day 2</time_frame>
    <description>To quantify the effects of sevoflurane on pro-inflammatory cytokine levels during ARDS-CoVid19</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IL-8</measure>
    <time_frame>Day 2</time_frame>
    <description>To quantify the effects of sevoflurane on pro-inflammatory cytokine levels during ARDS-CoVid19</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>Day 30</time_frame>
    <description>To evaluate the 30-day mortality.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Acute Respiratory Distress Syndrome</condition>
  <condition>COVID19 Infection</condition>
  <arm_group>
    <arm_group_label>SEVOFLURANE Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>PROPOFOL Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sevoflurane</intervention_name>
    <description>25 patients sedated with Sevoflurane via inhalation, starting with 6 ml/h and changing every 15 minutes until an adequate level of sedation is achieved ( BIS 40-50)</description>
    <arm_group_label>SEVOFLURANE Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Propofol</intervention_name>
    <description>25 patients standard sedation with intravenous propofol, starting with 2 mg/kg/h and changing every 15 minutes until an adequate level of sedation is achieved ( BIS 40-50)</description>
    <arm_group_label>PROPOFOL Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18 years or more.

          -  Diagnosis of Acute Respiratory Distress Syndrome caused by COVID19 infection.

          -  Signature of Patient's Consent or Verbal Consent of Legal Representative

        Exclusion Criteria:

          -  Intracranial hypertension

          -  Hypersensitivity to the active ingredient (propofol or sevoflurane) or to any of the
             excipients

          -  Current volume &lt; 250ml

          -  History of malignant hyperthermia

          -  Liver failure

          -  Neutropenia (&lt;0.5x109)

          -  Pregnant or lactating women

          -  Have received chemotherapy in the last month since their inclusion in the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Rafael Badenes, PhD</last_name>
    <phone>0034961973500</phone>
    <email>rafaelbadenes@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital Universitario Ramón y Cajal</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Pestaña</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Paz</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Emilio Maseda, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico Universitario de Valencia</name>
      <address>
        <city>Valencia</city>
        <zip>46010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rafael Badenes, PhD</last_name>
      <email>rafaelbadenes@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico Universitario de Valencia</name>
      <address>
        <city>Valencia</city>
        <zip>46010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>José Manuel Segura</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario de Valencia</name>
      <address>
        <city>Valencia</city>
        <zip>46014</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jaume Puig, PhD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 21, 2020</study_first_submitted>
  <study_first_submitted_qc>April 21, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 24, 2020</study_first_posted>
  <last_update_submitted>April 28, 2020</last_update_submitted>
  <last_update_submitted_qc>April 28, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 29, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Respiratory Distress Syndrome, Newborn</mesh_term>
    <mesh_term>Respiratory Distress Syndrome, Adult</mesh_term>
    <mesh_term>Acute Lung Injury</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Propofol</mesh_term>
    <mesh_term>Sevoflurane</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

